Pfizer (NY:<a title="Quote for Pfizer" href="https://markets.financialcontent.com/townhall/quote?Symbol=NY%3APFE">PFE )

This big pharma stock still faces significant challenges in the new year.

Topics Intellectual Property

Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026? ↗

Today 4:10 EST

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Topics Government World Trade

1 Stock Under $50 Worth Your Attention and 2 That Underwhelm

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Most active S&P500 stocks in Wednesday's session ↗

January 07, 2026

Via Chartmill

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

Topics Artificial Intelligence Economy Intellectual Property

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Topics Economy

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

SCHD looks well-positioned to outperform significantly if the economy turns south in 2026.

Worried About a K-Shaped Economy? Buy This Top Dividend ETF for 2026.

January 07, 2026

Via Barchart.com

Topics Artificial Intelligence ETFs Economy

This Could Be Key to Pfizer's Turnaround in 2026 ↗

January 07, 2026

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Topics Intellectual Property

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

2 Safe-and-Steady Stocks with Competitive Advantages and 1 We Turn Down

January 06, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

January 06, 2026

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

Topics Economy

Pfizer's Quarterly Earnings Preview: What You Need to Know

January 06, 2026

Via Barchart.com

Topics Intellectual Property

5 of the Safest Ultra-High-Yield Dividend Stocks You Can Confidently Buy for 2026 ↗

January 06, 2026

Five sensational income stocks -- sporting yields ranging from 5.3% to 13.1% -- can fatten investors' pocketbooks in the new year.

There were nice companies and great CEOs in 2025, but also some duds. We discuss the stocks on each list and end by going shopping for stocks.

Topics Bonds

Motley Fool Money: Stock Market Naughty and Nice List ↗

January 06, 2026

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

Topics Artificial Intelligence

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Via Stocktwits

2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid

January 05, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over...

Topics Stocks

1 Healthcare Stock to Target This Week and 2 We Turn Down

January 05, 2026

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

Topics Stocks

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Via Stocktwits

Topics Government

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

Looking for the most active stocks in the S&P500 index on Monday? ↗

January 05, 2026

Via Chartmill

This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping) ↗

January 05, 2026

Investors seem to be underestimating this company's foreseeable future.

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever ↗

January 05, 2026

Via MarketBeat

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 05, 2026

Both Ford and Pfizer have very attractive dividend yields.

Better Dividend Stock: Ford vs. Pfizer ↗

January 05, 2026

Another year, another long list of great dividend stocks.

Topics Economy Electric Vehicles Government

26 Top Dividend Stocks to Buy and Hold in 2026 ↗

January 05, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Topics Intellectual Property

3 Stocks Under $50 with Questionable Fundamentals

January 04, 2026

Income investors probably don't need to worry about a dividend cut from Pfizer in the new year.

How Safe Is Pfizer's Dividend As 2026 Begins? ↗

January 03, 2026

The company's prospects are stronger than its stock-market performance in 2025 suggests.

2 Predictions for Pfizer in 2026 ↗

January 02, 2026